Aurinia Pharmaceuticals Advances Voclosporin Study in Young Lupus Nephritis Patients

Aurinia Pharmaceuticals ((AUPH)) announced an update on their ongoing clinical study.

Study Overview: Aurinia Pharmaceuticals is conducting a study titled An Open-Label Extension Study to Assess the Long-Term Safety and Efficacy of Voclosporin in Adolescent and Pediatric Subjects With Lupus Nephritis. The study aims to evaluate the long-term safety and tolerability of voclosporin over an additional 12 months in young patients who have completed previous treatment for lupus nephritis. This research is significant as it addresses the need for effective long-term treatment options for this condition in younger populations.

Intervention/Treatment: The study tests voclosporin, a drug given in capsule form, to assess its safety and efficacy. Participants will receive voclosporin alongside standard treatments like mycophenolate mofetil and steroids, with dosing adjustments allowed based on previous studies.

Study Design: This is an interventional study with a single-group model, meaning all participants receive the same treatment without a comparison group. There is no masking, so both researchers and participants know the treatment being administered. The primary goal is treatment-focused.

Study Timeline: The study began on June 21, 2023, and is currently enrolling by invitation. The primary completion and estimated study completion dates are set for June 16, 2025. These dates are crucial for tracking the study’s progress and anticipating when results might be available.

Market Implications: This study update could positively influence Aurinia Pharmaceuticals’ stock performance by demonstrating ongoing commitment to expanding voclosporin’s use in younger populations. Successful outcomes may enhance investor confidence and position the company favorably against competitors in the lupus nephritis treatment market.

The study is ongoing, with further details available on the ClinicalTrials portal.